share_log

Truist Securities Reiterates Buy on Biogen, Maintains $340 Price Target

Moomoo 24/7 ·  Mar 25 11:57

Truist Securities analyst Robyn Karnauskas reiterates Biogen (NASDAQ:BIIB) with a Buy and maintains $340 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment